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Abstract : Aim : We investigated whether preoperative or postoperative inflammatory markers and psoas mus-
cle index (PMI), and their change after surgery, could predict postoperative recurrence in gastric cancer (GC). 
Methods : Thirty-five patients who underwent curative gastrectomy for pStage II and III GC were retrospective-
ly reviewed. The relationship between neutrophil–lymphocyte ratio (NLR), prognostic nutritional index (PNI), 
Glasgow Prognostic Score (GPS), and PMI, as well as postoperative recurrence, was analyzed presurgery and 
at 6 months after surgery. Results : In the preoperative data, there was a significant association between post-
operative recurrence and high NLR, low total protein, low albumin, low PNI, and high GPS. In the data from 
6 months after surgery, there was a significant association between postoperative recurrence and high NLR, 
high C-reactive protein, and high GPS. The reduction in PMI at 6 months after surgery relative to preoperative 
data was significantly greater in the cases with recurrence than in those without recurrence. No patients whose 
PMI increased compared with presurgery had recurrence. Conclusions : The postoperative reduction in PMI at 
6 months after surgery relative to presurgery could be a predictive marker of recurrence after curative gastrec-
tomy for patients with pStage II and III GC. J. Med. Invest. 68 : 119-124, February, 2021
Keywords : Gastric cancer, Recurrence, Psoas muscle index (PMI), Sarcopenia, Systemic inflammatory markers
INTRODUCTION
 
Gastric cancer (GC) is one of the most common malignancies 
and is the third-leading cause of malignancy-related death in the 
world (1). Although the clinical outcome of patients with GC has 
improved their disease-free status following curative resection 
and postoperative adjuvant chemotherapy (2), there is still much 
room for further improvement (3). To develop a perioperative 
treatment strategy for GC, it is important to identify predictors 
of its recurrence.
Assessment of prognostic efficacy of systemic inflammatory 
factors is meaningful to managing patients with GC (4). Several 
previous reports have revealed that comprehensive systemic 
inflammatory markers, including the prognostic nutritional 
index (PNI), Glasgow Prognostic Score (GPS), and neutrophil–
lymphocyte ratio (NLR), were independent predictors of survival 
in patients with GC (4-6). Many reports have only focused on 
the association between preoperative systemic inflammatory 
factors and prognoses (7-9). However, systemic inflammatory 
factors can drastically change after radical surgery for GC, and 
its association with patients’ prognoses is an unresolved issue 
(10). From the perspective of cancer recurrence, we considered 
the importance of postoperative comprehensive systemic inflam-
matory markers.
Sarcopenia is defined as a reduction in skeletal muscle mass 
with aging (10), and it is recognized as an important factor in 
cancer management. In GC, several reports have been published 
focusing on the association between cancer and sarcopenia (11-
15). Many GC studies have focused only on the association be-
tween preoperative sarcopenia and postoperative complications 
and / or prognoses, and the cutoff points, such as psoas muscle 
index (PMI) and skeletal muscle mass index, have varied from 
report to report (16-19). Therefore, further research is needed to 
clarify the clinical significance of sarcopenia in GC.
Although much evidence has been accumulated concerning 
the significance of inflammatory markers and sarcopenia in 
patients with GC, few reports have investigated the importance 
of their evaluation postsurgery or of their change between 
presurgery and postsurgery. The purpose of this study was to 
clarify the predictive impact of inflammatory markers and PMI 
on postoperative recurrence in patients with pStage II and III 
GC. In this study, we focused on both preoperative and 6 months 
postoperative data, as well as the difference between presurgery 
and 6 months after surgery.
PATIENTS AND METHODS
Patients
A total of 35 patients who underwent curative surgery for 
pStage II and III GC between 2010 and 2014 at the Numata Na-
tional Hospital Department of Surgery in Numata, Japan, were 
retrospectively reviewed. The patients with GC were staged 
according to the Japanese Classification of Gastric Carcinoma 
(20). Data were collected on patient characteristics, such as age, 
sex, height, body weight, and body mass index (BMI). In addi-
tion, both surgical information (such as surgical methods, lymph 
node dissection, operative time, and blood loss) and pathological 
information (such as depth of tumor invasion and lymph node 
metastasis) were recorded. This study was approved by the insti-
tutional review board of Numata National Hospital. 
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Assessment of systemic inflammatory markers
Results from laboratory tests, such as white blood cell count, 
NLR, hemoglobin, total protein (TP), albumin, and C-reac-
tive protein (CRP) were collected both before surgery and at 6 
months after surgery. The PNI was calculated as 10 × albumin + 
0.05 × lymphocyte count (21). The GPS was decided on the basis 
of CRP and albumin. Patients with elevated CRP ( > 0.3 mg / dL) 
and reduced albumin ( < 3.5 mg / dL) were assigned a score of 
2 points. Patients who had either of these two factors were 
assigned a score of 1 point. Patients who had neither of these 
factors were assigned a score of 0 points (22).
Assessment of sarcopenia
Computed tomography (CT) was performed in all cases at 
preoperative staging and at 6 months after surgery as a routine 
follow-up. The third lumbar vertebra (L3) was chosen as an eval-
uation point. The PMI was defined as the cross-sectional area of 
muscle at the L3 level normalized on the basis of patients’ height 
(cm2 / m2). Sarcopenia was defined as a PMI of <  6.0 cm2 / m2 for 
men and of < 3.4 cm2  /  m2 for women (23). We also set the value 
of preoperative PMI at 100% and calculated the percentage at 6 
months after surgery relative to preoperative data.
Statistical analysis
Statistically significant differences were analyzed using 
a Mann–Whitney U test for continuous variables and a chi-
squared test for categorical variables. Univariate survival anal-
yses were performed using the Cox proportional hazards model. 
A probability value of < 0.05 was considered to be statistically 
significant. All analyses were performed using JMP Pro 12.0 
software (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics
Of the 35 patients, 21 were men. Mean age was 70.6 years 
(range 52.0–90.0 years). Mean BMI was 21.1 (range 14.3–24.8 
kg / m2). Of the 35 patients, the depth of tumor invasion was 
deeper than the subserosa in 32 patients, and 30 patients had 
lymph node metastasis. There were eight patients with pStage II 
(22.9%) and 27 patients with pStage III (77.1%). No patients had 
recurrence within 6 months after surgery. The surgical methods 
were distal gastrectomy in 21 (60.0%) patients and total gastrec-
tomy (TG) in 14 (40.0%) patients. Regarding the postoperative 
complications, there were no patients with higher than grade 3 
Clavien–Dindo classification. During the study period, S-1 was 
administered to 28 (80%) patients as postoperative adjuvant 
chemotherapy. The reasons for absence of postoperative adjuvant 
chemotherapy in the remaining 7 (20%) patients were advanced 
age, poor performance status, comorbid conditions, and an in-
ability to obtain consent.
Association between patients’ clinical data and postoperative 
recurrence
Recurrence was observed in 15 (42.9%) of 35 patients. The 
association between recurrence and clinicopathological features 
in the 35 patients with GC is shown in Table 1. There were 
significant associations between recurrence and the presence 
of lymph node metastasis (p = 0.013) and advanced pathological 
stage (p = 0.036). In contrast, there was no significant associa-
tion in terms of age, sex, BMI, depth of tumor invasion, operative 
method, lymph node dissection, blood loss, or administration of 
adjuvant chemotherapy with S-1. 
Systemic inflammatory factors and PMI at presurgery and 6 months 
after surgery with regard to recurrence
In the preoperative evaluation, there was a significant re-
lationship between postoperative recurrence and high NLR 
(p = 0.011), low TP (p = 0.025), and low albumin (p = 0.0077), as 
shown in Table 2. Regarding PNI and GPS, many recurrences 
were found in the cases with low PNI (p = 0.0041) and high GPS 
(p = 0.0011).
In terms of 6 months after surgery, there was a significant 
relationship between recurrence and high NLR (p = 0.013) and 
high CRP (p = 0.040). Regarding PNI and GPS, we found that 
GPS was significantly associated with recurrence (p = 0.046), 
whereas PNI was not.
There was no significant correlation between PMI and recur-
rence for either presurgery or 6 months after surgery.
 
Changes in systemic inflammatory factors and PMI between presur-
gery and at 6 months after surgery with regard to recurrence
The decrease in PMI at 6 months after surgery relative to 
preoperative data was significantly greater in the cases with 
recurrence than those without recurrence (96.8 ± 3.7% vs. 82.0 ± 
4.3%, p = 0.014), whereas no significant correlations were found 
in NLR, PNI, or GPS, as shown in Table 3.
 
Association between patients’ clinical data and the changes in PMI
Reductions in PMI were observed in 28 (80%) of 35 patients. 
The association between changes in PMI and clinicopathologi-
cal features in 35 patients with GC is shown in Table 4. There 
Table 1.　The relationship between clinicopathological features and 
postoperative recurrence in 35 GC patients.
Factors
Recurrence
P valueAbsent Present 
n = 20 n = 15
Age (years) 68.1 ± 2.0 73.9 ± 2.3 0.07
Gender
Male 12 9 1.00
Female 8 6
BMI (kg / m2) 20.5 ± 0.6 21.8 ± 0.6 0.15
Depth
M, SM, MP 3 0 0.06
SS, SE, SI 17 15
Lymph node metastasis
Absent 5 0 0.013*
Present 15 15
Stage
Ⅱ 7 1 0.036*
Ⅲ 13 14
Operative method
Distal gastrectomy 13 8 0.49
Total gastrectomy 7 7
Lymph node dissection
D1, D1+ 6 8 0.18
D2 12 6
Operative time (min) 329.1 ± 19.7 377.7 ± 25.3 0.14
Blood loss (ml) 393.6 ± 82.2 542.5 ± 105.2 0.27
Adjuvant chemotherapy
Not-performed 3 4 0.4
Performed 17 11
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Table 3.　Changes of PMI and systemic inflammatory factors from 





 (n = 20)
Present
 (n = 15)
NLR
% 63.9 ± 9.2 66.6 ± 10.6 0.85
PNI
% 87.4 ± 9.0 96.3 ± 10.3 0.52
GPS
Increase 0 2 0.064
Same / Decrease 19 13
PMI
% 96.8 ± 3.7 82.0 ± 4.3 0.014*
NLR Neutrophil-to-Lymphocyte Ratio, PNI Prognostic Nutritional 
Index, GPS Glasgow Prognostic Score, Each percentage was calculated 
as following ; the value at 6 months after operation / the value before 
operation × 100.




6 months after operation
P valueRecurrence Recurrence
Absent (n = 20) Present (n = 15) Absent (n = 20) Present (n = 15)
White Blood Cell (WBC)
mm3 5873.5 ± 407.5 6596.0 ± 470.6 0.25 4211.5 ± 372.1 5340.7 ± 429.7 0.055
NLR
2.2 ± 0.3 3.6 ± 0.4 0.011* 1.2 ± 0.2 2.0 ± 0.2 0.013*
Hemoglobin
g / dl 12.4 ± 0.6 11.1 ± 0.7 0.16 11.8 ± 0.4 11.4 ± 0.7 0.57
Total Protein
g / dl 7.0 ± 0.2 6.3 ± 0.2 0.025 7.0 ± 0.1 6.8 ± 0.2 0.22
Albumin
g / dl 4.3 ± 0.1 3.7 ± 0.2 0.0077* 4.4 ± 0.1 4.1 ± 0.11 0.12
C-reactive protein
mg / dl 0.06 ± 0.2 0.7 ± 0.2 0.050 0.05 ± 0.08 0.3 ± 0.09 0.040*
PNI
Score 51.1 ± 1.6 43.7 ± 1.8 0.0041* 52.4 ± 1.5 50.0 ± 1.8 0.31
GPS
Score 0.0 ± 0.1 0.7 ± 0.1 0.0011* 0.0 ± 0.1 0.3 ± 0.1 0.046*
PMI
Score 4.2 ± 0.3 3.9 ± 0.4 0.52 4.1 ± 0.4 3.2 ± 0.5 0.14
Sarcopenia 
(Using PMI cut-off point)  
Non-sarcopenia 6 3 0.50 3 0 0.06
Sarcopenia 14 12 17 15
NLR Neutrophil-to-Lymphocyte Ratio, PNI  Prognostic Nutritional Index, GPS Glasgow Prognostic Score, PMI cut-off point 6.0cm2/ m2 (men) 
and 3.4cm2 / m2 (women) 
Table 4.　The relationship between clinicopathological features and 
PMI decrease or increase compared to before operation.
Factors
PMI
P valueDecrease Increase 
n = 28 n = 7
Age (years) 70.6 ± 1.8 70.3 ± 3.6 0.93
Gender
Male 17 4 0.86
Female 11 3
BMI (kg / m2) 21.1 ± 0.5 21.1 ± 1.0 0.94
Depth
M, SM, MP 3 0 0.55
SS, SE, SI 25 7
Lymph node metastasis
Absent 2 3 0.030*
Present 26 4
Stage
Ⅱ 7 1 0.53
Ⅲ 21 6
Operative method
Distal gastrectomy 16 5 0.48
Total gastrectomy 12 2
Adjuvant chemotherapy
Not-performed 5 2 0.54
Performed 23 5
Recurrence
Absent 13 7 0.0025*
Present 15 0
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were significant associations between reduced PMI and the 
presence of lymph node metastasis (p = 0.030) and postoperative 
recurrence (p = 0.0025). All the patients with increased PMI 
compared with presurgery had no recurrence.
Association between systemic inflammatory factors and changes in 
PMI
Patients with increased PMI had significantly lower pre-
operative NLR (p = 0.040), as shown in Table 5. However, no 
significant correlation was observed at 6 months after surgery in 
patients with increased PMI.
DISCUSSION
In this study, we analyzed systemic inflammatory markers 
and PMI at presurgery and at 6 months after surgery in patients 
with GC with pStage II and III in terms of postoperative recur-
rence. There was significant association between postoperative 
recurrence and high NLR, low TP, low albumin, low PNI, and 
high GPS in the preoperative evaluation, whereas high NLR, 
high CRP, and high GPS were shown in the data for postop-
erative recurrence at 6 months after surgery. There were sig-
nificant associations between postoperative reductions in PMI 
and the presence of lymph node metastasis and postoperative 
recurrence. Furthermore, no cases with postoperative increase 
of PMI had recurrence. Our results suggest that sarcopenia and 
inflammatory markers should be evaluated at multiple points 
peri-operation because they are changeable depending on pa-
tients’ background factors.
NLR is reported to be strongly associated with sarcopenia 
(24). In our research, it was useful to predict recurrence both 
preoperatively and at 6 months after surgery. PNI and GPS 
are also known as significant predictors of the prognosis in GC 
(4) ; however, the effectiveness of evaluation at 6 months after 
surgery is poorly understood. Regarding PNI and GPS, we 
found that GPS was significantly associated with recurrence 
(p = 0.046) at 6 months after surgery, whereas PNI was not. The 
following two reasons were considered : First, TP and albumin 
tended to improve after surgery, which could have influenced 
PNI. Second, CRP had an association with recurrence at 6 
months after surgery, affecting the positive correlation between 
GPS and recurrence. We should note the change in NLR and 
CRP in order to predict recurrence at 6 months after surgery.
Previous studies have focused on the effect of sarcopenia on 
GC outcomes (13, 25, 26). However, there were variations in 
the sarcopenia evaluation point, cutoff point, patient’s back-
ground, and study design in each paper. To clarify whether PMI 
and systemic inflammatory markers had a relationship with 
recurrence, we focused on patients with pStage II or III GC in 
this study. In this study, 24 (68.6%) patients were older than 65 
years. As mentioned earlier, sarcopenia was defined as a PMI of 
< 6.0 cm2 / m2 for men and < 3.4 cm2 / m2 for women (23). When we 
adopted these cutoff points, 26 (74.3%) patients and 32 (91.4%) 
patients were defined as having sarcopenia presurgery and at 6 
months after surgery, respectively. We did not find a significant 
association between recurrence and sarcopenia while employing 
the cutoff point of PMI. Kiyama T et al. had shown a significant 
loss of body protein of 8% at 6 months after TG (27). Yamaoka Y 
et al. had also found that approximately 25% of patients showed 
a significant loss of skeletal muscle of > 10% at 1 year after TG 
(28). Therefore, we set the value of preoperative PMI as 100% 
Table 5.　Systemic inflammatory factors at the point of before operation and 6 months after operation with regard to PMI decrease or increase 




6 months after operation
P valuePMI PMI
Decrease (n = 28) Increase (n = 7) Decrease (n = 28) Increase (n = 7)
White Blood Cell (WBC)
mm3 6360.7 ± 344.5 5472.9 ± 689.1 0.26 4763.6 ± 331.7 4422.9 ± 663.4 0.65
NLR
3.0 ± 0.3 1.6 ± 0.6 0.040* 1.6 ± 0.2 1.2 ± 0.4 0.4
Hemoglobin
g / dl 11.9 ± 0.5 11.7 ± 1.0 0.90 11.7 ± 0.4 11.6 ± 0.7 0.94
Total Protein
g / dl 6.7 ± 0.2 6.7 ± 0.3 0.91 6.9 ± 0.1 7.2 ± 0.2 0.22
Albumin
g / dl 4.0 ± 0.1 4.1 ± 0.2 0.85 4.2 ± 0.1 4.4 ± 0.2 0.25
C-reactive protein
mg / dl 0.39 ± 0.2 0.05 ± 0.3 0.38 0.19 ± 0.07 0.04 ± 0.1 0.34
PNI
Score 47.4 ± 1.5 49.9 ± 3.0 0.45 51.2 ± 1.3 52.1 ± 2.6 0.77
GPS
Score 0.4 ± 0.1 0.0 ± 0.2 0.17 0.2 ± 0.1 0.0 ± 0.2 0.40
PMI
Score 4.1 ± 0.3 4.1 ± 0.5 0.94 3.4 ± 0.3 5.2 ± 0.7 0.023*
Sarcopenia 
(Using PMI cut-off point)  
Non-sarcopenia 6 3 0.26 0 3 0.0010*
Sarcopenia 22 4 28 4
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and calculated the percentage at 6 months after surgery relative 
to preoperative data. We found that PMI was significantly lower 
at 6 months after surgery in cases with recurrence (96.8 ± 3.7% 
vs. 82.0 ± 4.3%). The receiver operating characteristic curve 
constructed to investigate the association between the transition 
of PMI and recurrence demonstrated that the cutoff point was 
93.0%. This cutoff meant that cases with a PMI reduction of 
> 7% had a relative risk of recurrence. In this way, preventing 
the loss of PMI after surgery could lead to improved patient 
outcomes. Furthermore, focusing on the transition of PMI is 
valuable because it is independent of the patient’s age. Given 
sarcopenia and GC prognoses are related, early nutritional sta-
tus assessments are useful (26, 29). Proinflammatory cytokines, 
including interleukin (IL)-1, IL-6, and tumor necrosis factor-α, 
were found to be mediators of skeletal muscle proteolysis loss 
and are the components of sarcopenia (30). Okumura S et al. 
suggested that decreasing muscle mass should give rise fewer 
cytokines which causes decreased immunity (31). Lutz CT et al. 
also reported that decreased cytokine levels suppress the func-
tion of natural killer cells in sarcopenia (32). Evaluation of these 
proinflammatory cytokines after surgery might be meaningful.
Our study has some limitations. It had a small sample size, 
which could bias the results. Further large-scale clinical trials 
are needed to clarify the potential of the transition of PMI as a 
new predictive biomarker for GC recurrence. Also, the diagnosis 
of sarcopenia requires measurement of walking speed and grip 
strength (33, 34), but it is difficult to evaluate in those with poor 
physical condition and in the elderly. We focused on CT, which is 
frequently used in GC management. The significance of walking 
speed and grip strength to evaluate postoperative change of sar-
copenia could be further investigated.
In conclusion, the transition of PMI was significantly cor-
related with recurrence in pStage II and III patients with GC. 
Furthermore, evaluating systemic inflammatory factors, such as 
NLR, PNI, and GPS, was also considered important. NLR and 
GPS were useful predictive markers both preoperatively and at 
6 months after surgery. In particular, the change in PMI at 6 
months after surgery compared with presurgery was a useful 
prognostic predictor. Given CT is performed for preoperative 
staging and postoperative follow-up in almost all cases of GC, 
the findings can be used to identify changes in skeletal muscle 
and provide nutritional assessment, which could improve clinical 
outcomes.
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